Policy
BIO unveils plan for US to remain biotech’s ‘global leader’
BioPharma Dive · By Gwendolyn Wu ·
The Brief
- BIO, a prominent biotech lobbying group, unveiled a seven-part proposal.
- The plan aims to keep the US the leader in biotech and to accelerate drug development in the country.
- The proposal is framed as a response to China's fast rise in biotech.
Why it matters
The proposal could shape US rules and incentives for drug development and clinical trials, affecting how quickly new therapies reach patients and how the US competes with China in biotech research.
Who’s affected
- biotech researchers and drug developers
- US policymakers and regulators
- clinical trial sponsors
- #biotech
- #drug-development
- #clinical-trials
- #us-policy
- #china
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
Timeline
BIO unveiled its seven-part plan to keep the US the global leader in biotech
BioPharma Dive - Latest News
BIO unveils plan for US to remain biotech’s ‘global leader’